XELJANZ XR FDA label update (2026-07-12)

2 min read Jul 15, 2026, 8:11 PM

Medications Tofacitinib Immunomodulators JAK inhibitor Regulatory Update Adult patients Clinicians Patients On Biologics

Why This Matters

The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK inhibitor.

Who Should Pay Attention

Adult patients with ulcerative colitis or other autoimmune diseases being treated with or considering tofacitinib (XELJANZ/XR); clinicians who prescribe JAK inhibitors; patients on or switching from biologics/TNF blockers.

Study Snapshot

Story typeRegulatory

Evidence typeRegulatory update

Study statusHuman prescription drug

Source depthRegulatory record

What To Know

The updated prescribing information emphasizes safety risks tied to tofacitinib (marketed as XELJANZ/XELJANZ XR), including higher rates of certain cancers, cardiovascular events, and clotting events compared with TNF blockers in some RA studies.

It also reiterates that patients can develop serious infections (including TB) and should be tested for latent TB before and during treatment. The label notes limitations of use (for example, not to combine with biologic DMARDs or potent immunosuppressants) and includes pediatric indications for some formulations.

Practical points: If you are a patient taking or considering XELJANZ/XR, these label updates are about safety information and monitoring — discuss risks, monitoring plans (including TB testing), and alternative treatments with your clinician.

If you are a clinician, review the full prescribing information for boxed warnings, recommended testing, and specific limitations of use.

Keep In Mind

This record is the official prescribing information (drug label) posted on DailyMed and reflects FDA-regulated indications, boxed warnings, and monitoring recommendations. It reports class-specific safety findings (some comparisons vs TNF blockers) drawn from regulatory review and studies; consult your clinician for personalized interpretation.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source

Regulatory update Evidence type derived from source or registry metadata.

PublicationopenFDA

PublisherU.S. Food and Drug Administration

SponsorPfizer Laboratories Div Pfizer Inc

Study typeDrug Label Update

Indexed viaopenFDA

Source typeRegulatory record

PublishedJul 12, 2026, 12:00 AM

Content availableRegulatory record

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.